A new research collaboration aimed at advancing the understanding of mitochondrial disease has received funding support through the UK’s Medical Research Council (MRC), marking a significant step forward in efforts to tackle complex genetic conditions.
The project, involving Stealth BioTherapeutics and leading academic institutions including University College London, will focus on investigating potential treatments for conditions linked to mitochondrial dysfunction.
At the centre of the research is a compound known as SBT-589, which will be studied in preclinical models to assess its impact on survival rates, motor function and disease biomarkers. The work will also involve collaboration with the MRC’s National Mouse Genetics Network and the Mary Lyon Centre.
Mitochondrial diseases affect the body’s ability to produce energy at a cellular level, often leading to severe neurological and muscular symptoms. Conditions such as Leigh syndrome can be particularly devastating, with limited treatment options currently available.
Researchers hope that the new study will provide valuable insights into how targeted therapies can improve outcomes for patients. By combining academic expertise with industry-led drug development, the collaboration aims to accelerate progress in a field where advances have historically been slow.
The funding forms part of the MRC’s Business Engagement Fund, which supports partnerships between research institutions and commercial organisations. The initiative is designed to bridge the gap between scientific discovery and practical application.
Scientists involved in the project say the collaboration represents an important opportunity to explore new treatment pathways and deepen understanding of mitochondrial disease mechanisms.
If successful, the research could contribute to the development of new therapies for patients with currently unmet medical needs.